291 related articles for article (PubMed ID: 19192944)
1. Survival-related profile, pathways, and transcription factors in ovarian cancer.
Crijns AP; Fehrmann RS; de Jong S; Gerbens F; Meersma GJ; Klip HG; Hollema H; Hofstra RM; te Meerman GJ; de Vries EG; van der Zee AG
PLoS Med; 2009 Feb; 6(2):e24. PubMed ID: 19192944
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets.
Yoshihara K; Tajima A; Yahata T; Kodama S; Fujiwara H; Suzuki M; Onishi Y; Hatae M; Sueyoshi K; Fujiwara H; Kudo Y; Kotera K; Masuzaki H; Tashiro H; Katabuchi H; Inoue I; Tanaka K
PLoS One; 2010 Mar; 5(3):e9615. PubMed ID: 20300634
[TBL] [Abstract][Full Text] [Related]
3. Unique gene expression profile based on pathologic response in epithelial ovarian cancer.
Spentzos D; Levine DA; Kolia S; Otu H; Boyd J; Libermann TA; Cannistra SA
J Clin Oncol; 2005 Nov; 23(31):7911-8. PubMed ID: 16204010
[TBL] [Abstract][Full Text] [Related]
4. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
5. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
[TBL] [Abstract][Full Text] [Related]
6. Gene expression signature with independent prognostic significance in epithelial ovarian cancer.
Spentzos D; Levine DA; Ramoni MF; Joseph M; Gu X; Boyd J; Libermann TA; Cannistra SA
J Clin Oncol; 2004 Dec; 22(23):4700-10. PubMed ID: 15505275
[TBL] [Abstract][Full Text] [Related]
7. Integrated analysis of multiple microarray datasets identifies a reproducible survival predictor in ovarian cancer.
Konstantinopoulos PA; Cannistra SA; Fountzilas H; Culhane A; Pillay K; Rueda B; Cramer D; Seiden M; Birrer M; Coukos G; Zhang L; Quackenbush J; Spentzos D
PLoS One; 2011 Mar; 6(3):e18202. PubMed ID: 21479231
[TBL] [Abstract][Full Text] [Related]
8. Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer.
Benvenuto G; Todeschini P; Paracchini L; Calura E; Fruscio R; Romani C; Beltrame L; Martini P; Ravaggi A; Ceppi L; Sales G; Donati F; Perego P; Zanotti L; Ballabio S; Grassi T; Delle Marchette M; Tognon G; Sartori E; Adorni M; Odicino F; D'Incalci M; Bignotti E; Romualdi C; Marchini S
Int J Cancer; 2020 Jul; 147(2):565-574. PubMed ID: 32096871
[TBL] [Abstract][Full Text] [Related]
9. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
Tothill RW; Tinker AV; George J; Brown R; Fox SB; Lade S; Johnson DS; Trivett MK; Etemadmoghadam D; Locandro B; Traficante N; Fereday S; Hung JA; Chiew YE; Haviv I; ; Gertig D; DeFazio A; Bowtell DD
Clin Cancer Res; 2008 Aug; 14(16):5198-208. PubMed ID: 18698038
[TBL] [Abstract][Full Text] [Related]
10. Downregulated Long Noncoding RNA DGCR5 Acts as a New Promising Biomarker for the Diagnosis and Prognosis of Ovarian Cancer.
Chen H; Tian X; Luan Y; Lu H
Technol Cancer Res Treat; 2019; 18():1533033819896809. PubMed ID: 31868103
[TBL] [Abstract][Full Text] [Related]
11. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
[TBL] [Abstract][Full Text] [Related]
12. Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.
Mignogna C; Staropoli N; Botta C; De Marco C; Rizzuto A; Morelli M; Di Cello A; Franco R; Camastra C; Presta I; Malara N; Salvino A; Tassone P; Tagliaferri P; Barni T; Donato G; Di Vito A
J Ovarian Res; 2016 May; 9(1):31. PubMed ID: 27209210
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis.
Yoshihara K; Tajima A; Komata D; Yamamoto T; Kodama S; Fujiwara H; Suzuki M; Onishi Y; Hatae M; Sueyoshi K; Fujiwara H; Kudo Y; Inoue I; Tanaka K
Cancer Sci; 2009 Aug; 100(8):1421-8. PubMed ID: 19486012
[TBL] [Abstract][Full Text] [Related]
15. Integrative prognostic subtype discovery in high-grade serous ovarian cancer.
Xie H; Xu H; Hou Y; Cai Y; Rong Z; Song W; Wang W; Li K
J Cell Biochem; 2019 Nov; 120(11):18659-18666. PubMed ID: 31347734
[TBL] [Abstract][Full Text] [Related]
16. Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival.
Brenne K; Nymoen DA; Hetland TE; Trope' CG; Davidson B
Hum Pathol; 2012 Apr; 43(4):496-505. PubMed ID: 21855111
[TBL] [Abstract][Full Text] [Related]
17. Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome.
Berchuck A; Iversen ES; Luo J; Clarke JP; Horne H; Levine DA; Boyd J; Alonso MA; Secord AA; Bernardini MQ; Barnett JC; Boren T; Murphy SK; Dressman HK; Marks JR; Lancaster JM
Clin Cancer Res; 2009 Apr; 15(7):2448-55. PubMed ID: 19318476
[TBL] [Abstract][Full Text] [Related]
18. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.
Cohen S; Mosig R; Moshier E; Pereira E; Rahaman J; Prasad-Hayes M; Halpert R; Billaud JN; Dottino P; Martignetti JA
Gynecol Oncol; 2014 Sep; 134(3):591-8. PubMed ID: 24995581
[TBL] [Abstract][Full Text] [Related]
19. Identification of metastasis and prognosis-associated genes for serous ovarian cancer.
Yang Y; Qi S; Shi C; Han X; Yu J; Zhang L; Qin S; Gao Y
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32510146
[TBL] [Abstract][Full Text] [Related]
20. High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway.
Yoshihara K; Tsunoda T; Shigemizu D; Fujiwara H; Hatae M; Fujiwara H; Masuzaki H; Katabuchi H; Kawakami Y; Okamoto A; Nogawa T; Matsumura N; Udagawa Y; Saito T; Itamochi H; Takano M; Miyagi E; Sudo T; Ushijima K; Iwase H; Seki H; Terao Y; Enomoto T; Mikami M; Akazawa K; Tsuda H; Moriya T; Tajima A; Inoue I; Tanaka K;
Clin Cancer Res; 2012 Mar; 18(5):1374-85. PubMed ID: 22241791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]